<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": italic;} Infect ChemotherInfect ChemotherICInfection &amp;amp; Chemotherapy2093-23402092-6448The Korean Society of" exact="Infectious" post="Diseases and Korean Society for Chemotherapy pmcid: 7533207 pmid:"/>
 <result pre="italic;} Infect ChemotherInfect ChemotherICInfection &amp;amp; Chemotherapy2093-23402092-6448The Korean Society of Infectious" exact="Diseases" post="and Korean Society for Chemotherapy pmcid: 7533207 pmid: 32989938"/>
 <result pre="doi: 10.3947/ic.2020.52.3.307 : Review Article Convalescent Plasma Therapy for Coronavirus" exact="Disease" post="2019 https://orcid.org/0000-0002-2775-3315ChoiJun Yong[], Korea Corresponding Author: Jun Yong Choi,"/>
 <result pre="+82-2-393-6884, seran@yuhs.ac ppub: 2020-9epub: 2020-9-9523307316received: 2020-8-07(C) The Korean Society of" exact="Infectious" post="Diseases, Korean Society for Antimicrobial Therapy, and The Korean"/>
 <result pre="for decades to prevent and treat a wide range of" exact="infectious diseases" post="for which no specific treatment is available. The use"/>
 <result pre="transfusing plasma collected from patients who have recovered from a" exact="viral" post="illness, in an attempt to transfer virus-neutralizing antibodies and"/>
 <result pre="effects of convalescent plasma for the treatment of severe coronavirus" exact="disease" post="2019 (COVID-19). In addition to transfusion-related side effects, unexpected"/>
 <result pre="be considered as a candidate therapy for COVID-19 given the" exact="limited" post="effectiveness of antiviral drugs and lack of a vaccine."/>
 <result pre="of convalescent plasma therapy concurrently with its clinical use. Coronavirus" exact="disease" post="2019 Severe acute respiratory syndrome coronavirus 2 COVID-19 serotherapy"/>
 <result pre="plasma therapy concurrently with its clinical use. Coronavirus disease 2019" exact="Severe" post="acute respiratory syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction"/>
 <result pre="therapy concurrently with its clinical use. Coronavirus disease 2019 Severe" exact="acute" post="respiratory syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction Severe"/>
 <result pre="concurrently with its clinical use. Coronavirus disease 2019 Severe acute" exact="respiratory" post="syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction Severe acute"/>
 <result pre="with its clinical use. Coronavirus disease 2019 Severe acute respiratory" exact="syndrome" post="coronavirus 2 COVID-19 serotherapy Plasma Introduction Severe acute respiratory"/>
 <result pre="Severe acute respiratory syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become"/>
 <result pre="acute respiratory syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become a"/>
 <result pre="respiratory syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection has become a global"/>
 <result pre="syndrome coronavirus 2 COVID-19 serotherapy Plasma Introduction Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection has become a global concern,"/>
 <result pre="serotherapy Plasma Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="has become a global concern, and the World Health"/>
 <result pre="global concern, and the World Health Organization (WHO) declared coronavirus" exact="disease" post="2019 (COVID-19) a Public Health Emergency of International Concern"/>
 <result pre="more than 660,000 deaths. Most patients with COVID-19 have mild" exact="disease" post="and recover without any treatment. However, older individuals with"/>
 <result pre="without any treatment. However, older individuals with comorbidities such as" exact="diabetes mellitus," post="hypertension, and respiratory or cardiovascular disease are at greater"/>
 <result pre="older individuals with comorbidities such as diabetes mellitus, hypertension, and" exact="respiratory" post="or cardiovascular disease are at greater risk of complications"/>
 <result pre="with comorbidities such as diabetes mellitus, hypertension, and respiratory or" exact="cardiovascular disease" post="are at greater risk of complications and mortality [23]."/>
 <result pre="comorbidities such as diabetes mellitus, hypertension, and respiratory or cardiovascular" exact="disease" post="are at greater risk of complications and mortality [23]."/>
 <result pre="therapeutic options for COVID-19 and vaccines, historical interventions for emerging" exact="infectious diseases" post="have remerged as options for disease control. Given its"/>
 <result pre="interventions for emerging infectious diseases have remerged as options for" exact="disease" post="control. Given its rapid acquisition, convalescent plasma therapy has"/>
 <result pre="emergency intervention in several pandemics, including the Spanish flu, severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV-1), and West Nile virus, and"/>
 <result pre="intervention in several pandemics, including the Spanish flu, severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV-1), and West Nile virus, and more"/>
 <result pre="in several pandemics, including the Spanish flu, severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV-1), and West Nile virus, and more recently,"/>
 <result pre="twentieth century, convalescent sera were used to stem epidemics of" exact="viral" post="diseases such as poliomyelitis, measles, mumps, and influenza [10]."/>
 <result pre="influenza virus pandemic suggested that those who received serum had" exact="lower" post="mortality [11]. During the 2009 - 2010 H1N1 influenza"/>
 <result pre="convalescent plasma was used to treat patients with severe H1N1" exact="infection" post="requiring critical care [12]. A study with 93 participants"/>
 <result pre="with 93 participants showed that treatment of severe H1N1 2009" exact="infection" post="with convalescent plasma reduced respiratory tract viral load, serum"/>
 <result pre="treatment of severe H1N1 2009 infection with convalescent plasma reduced" exact="respiratory" post="tract viral load, serum cytokine response, and mortality. During"/>
 <result pre="severe H1N1 2009 infection with convalescent plasma reduced respiratory tract" exact="viral" post="load, serum cytokine response, and mortality. During the 2013"/>
 <result pre="standard treatment [13]. However, another nonrandomized study on Ebola virus" exact="disease" post="did not show the survival benefit of convalescent plasma"/>
 <result pre="also been used for treating coronavirus diseases such as severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)."/>
 <result pre="been used for treating coronavirus diseases such as severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS). A"/>
 <result pre="used for treating coronavirus diseases such as severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS). A study"/>
 <result pre="such as severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS). A study from a hospital in Hong"/>
 <result pre="as severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS). A study from a hospital in Hong Kong"/>
 <result pre="experiences on convalescent plasma therapy for the treatment of emerging" exact="infectious diseases" post="provide us with important historical precedents that this intervention"/>
 <result pre="susceptible individual for the purpose of preventing or treating an" exact="infectious disease." post="Neutralizing antibodies have been considered essential in the effects"/>
 <result pre="amelioration of severe inflammatory response. Clinical studies on COVID-19 Several" exact="uncontrolled" post="case series of convalescent plasma therapy for the treatment"/>
 <result pre="of patients with COVID-19 have suggested a possible benefit [20212223]." exact="Multiple" post="studies have evaluated the effects of convalescent plasma therapy"/>
 <result pre="The reports showed that convalescent plasma therapy induced reduction in" exact="viral" post="loads and improvement of laboratory markers and clinical signs."/>
 <result pre="ongoing in many countries. As of August 3 2020, a" exact="total" post="of 132 studies evaluating the role of convalescent plasma"/>
 <result pre="group and the control group were not statistically significant. The" exact="primary" post="endpoint of time to clinical improvement within 28 days"/>
 <result pre="or having a reduction of 2 points on a 6-point" exact="disease" post="severity scale) was 2.15 days shorter (95% confidence interval"/>
 <result pre="CI:0.80 - 1.81; P = 0.37). In analyses stratified by" exact="disease" post="severity, among patients with severe disease (23 in the"/>
 <result pre="In analyses stratified by disease severity, among patients with severe" exact="disease" post="(23 in the convalescent plasma group and 22 in"/>
 <result pre="or requiring mechanical ventilation). Some of the patients with life-threatening" exact="disease" post="might have had irreversible disease at the time that"/>
 <result pre="of the patients with life-threatening disease might have had irreversible" exact="disease" post="at the time that plasma therapy was initiated. Table"/>
 <result pre="Nonrandomized, non-controlled study 4 100% improved None [22] COVID-19, coronavirus" exact="disease" post="2019. Although a recent systematic review showed uncertainty regarding"/>
 <result pre="blood-borne pathogens, and some severe adverse events such as transfusion-related" exact="acute" post="lung injury (TRALI), transfusion-associated circulatory overload (TACO), and antibody-dependent"/>
 <result pre="therapies are unavailable [31]. TACO and TRALI are syndromes of" exact="acute" post="respiratory distress that occur within 6 hours of blood"/>
 <result pre="are unavailable [31]. TACO and TRALI are syndromes of acute" exact="respiratory" post="distress that occur within 6 hours of blood transfusion."/>
 <result pre="fluid balance may precede circulatory overload. TRALI often presents as" exact="bilateral" post="pulmonary edema with little evidence of circulatory overload. TRALI"/>
 <result pre="balance may precede circulatory overload. TRALI often presents as bilateral" exact="pulmonary" post="edema with little evidence of circulatory overload. TRALI may"/>
 <result pre="to non-neutralizing or sub-neutralizing antibodies could lead to more efficient" exact="viral" post="uptake into the target cell in FcÎ³ receptor or"/>
 <result pre="in FcÎ³ receptor or through complement-mediated mechanisms, leading to enhanced" exact="viral" post="replication [3233]. ADE has been reported for various viral"/>
 <result pre="enhanced viral replication [3233]. ADE has been reported for various" exact="viral" post="diseases including dengue, Zika, influenza, and respiratory syncytial virus"/>
 <result pre="reported for various viral diseases including dengue, Zika, influenza, and" exact="respiratory" post="syncytial virus infection. The ADE phenomenon has been demonstrated"/>
 <result pre="various viral diseases including dengue, Zika, influenza, and respiratory syncytial" exact="virus infection." post="The ADE phenomenon has been demonstrated for SARS-CoV-1 using"/>
 <result pre="Patient and donor eligibility Most patients with COVID-19 have mild" exact="disease" post="and recover with conservative treatment only. Clinical studies on"/>
 <result pre="COVID-19 was suspected. (2) Either one of the following (i)" exact="Complete" post="resolution of symptoms at least 28 days prior to"/>
 <result pre="symptoms at least 28 days prior to donation; or (ii)" exact="Complete" post="resolution of symptoms at least 14 days prior to"/>
 <result pre="a molecular diagnostic test from blood. (3) Male donors, or" exact="female" post="donors who have not been pregnant, or female donors"/>
 <result pre="donors, or female donors who have not been pregnant, or" exact="female" post="donors who have been tested since their most recent"/>
 <result pre="be determined at a later date. The Korea Centers for" exact="Disease" post="Control (KCDC) has also developed donor eligibility criteria as"/>
 <result pre="real-time reverse transcription polymerase chain reaction for SARS-CoV-2 using a" exact="respiratory" post="specimen should be confirmed if the plasma collection is"/>
 <result pre="28 days after the donor has been cured of COVID-19." exact="Infectious" post="disease specialists and laboratory medicine specialists should confirm that"/>
 <result pre="days after the donor has been cured of COVID-19. Infectious" exact="disease" post="specialists and laboratory medicine specialists should confirm that the"/>
 <result pre="antibody titers in convalescent plasma Some patients who recover from" exact="viral" post="diseases may not have high titers of neutralizing antibodies,"/>
 <result pre="that virus-specific IgG levels in asymptomatic COVID-19 patients were significantly" exact="lower" post="than those in symptomatic patients in the acute phase"/>
 <result pre="in asymptomatic COVID-19 patients were significantly lower than those in" exact="symptomatic" post="patients in the acute phase [37]. Of asymptomatic individuals,"/>
 <result pre="were significantly lower than those in symptomatic patients in the" exact="acute" post="phase [37]. Of asymptomatic individuals, 93.3% and 81.1% had"/>
 <result pre="early convalescent phase, as compared to 96.8% and 62.2% of" exact="symptomatic" post="patients, respectively. Forty percent of asymptomatic individuals, and 12.9%"/>
 <result pre="patients, respectively. Forty percent of asymptomatic individuals, and 12.9% of" exact="symptomatic" post="individuals, became seronegative for IgG in the early convalescent"/>
 <result pre="plasma from 436 convalescent plasma donors with a history of" exact="disease" post="compatible with COVID-19 in England [39]. The study showed"/>
 <result pre="required. A population of donors who have recovered from the" exact="disease" post="and can donate convalescent serum need to be recruited."/>
 <result pre="disease and can donate convalescent serum need to be recruited." exact="Blood" post="banking facilities to process apheresis are necessary. Essential assays,"/>
 <result pre="be recruited. Blood banking facilities to process apheresis are necessary." exact="Essential" post="assays, including serological assays to detect SARS-CoV-2 antibodies in"/>
 <result pre="detect SARS-CoV-2 antibodies in serum, and virological assays to measure" exact="viral" post="neutralization, should be performed. To perform the assays for"/>
 <result pre="be considered as a candidate intervention for COVID-19, given the" exact="limited" post="evidence of effectiveness of antiviral agents and the lack"/>
 <result pre="review &amp;amp; editing: JYC. References 1collab: World Health Organization (WHO)Coronavirus" exact="disease" post="(COVID-19) pandemicAccessed 3 August 2020Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 2GuanWJNiZYHuYLiangWHOuCQHeJXLiuLShanHLeiCLHuiDSCDuBLiLJZengGYuenKYChenRCTangCLWangTChenPYXiangJLiSYWangJLLiangZJPengYXWeiLLiuYHuYHPengPWangJMLiuJYChenZLiGZhengZJQiuSQLuoJYeCJZhuSYZhongNScollab: China"/>
 <result pre="China Medical Treatment Expert Group for Covid-19Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN Engl J Med20203821708172032109013 3KangSJJungSIAge-related morbidity and"/>
 <result pre="convalescent plasma and hyperimmune immunoglobulin for the treatment of severe" exact="acute" post="respiratory infections of viral etiology: a systematic review and"/>
 <result pre="plasma and hyperimmune immunoglobulin for the treatment of severe acute" exact="respiratory" post="infections of viral etiology: a systematic review and exploratory"/>
 <result pre="and hyperimmune immunoglobulin for the treatment of severe acute respiratory" exact="infections" post="of viral etiology: a systematic review and exploratory meta-analysisJ"/>
 <result pre="immunoglobulin for the treatment of severe acute respiratory infections of" exact="viral" post="etiology: a systematic review and exploratory meta-analysisJ Infect Dis2015211809025030060"/>
 <result pre="meta-analysisJ Infect Dis2015211809025030060 8RojasMMonsalveDMPachecoYAcosta-AmpudiaYRamÃ­rez-SantanaCAnsariAAGershwinMEAnayaJMEbola virus disease: An emerging and re-emerging" exact="viral" post="threatJ Autoimmun202010610237531806422 9PlanitzerCBModrofJKreilTRWest Nile virus neutralization by US plasma-derived"/>
 <result pre="Dis20115244745621248066 13SahrFAnsumanaRMassaquoiTAIdrissBRSesayFRLaminJMBakerSNicolSContonBJohnsonWAbiriOTKargboOKamaraPGobaARussellJBGevaoSMEvaluation of convalescent whole blood for treating Ebola virus" exact="disease" post="in Freetown, Sierra LeoneJ Infect20177430230927867062 14van GriensvenJEdwardsTde LamballerieXSempleMGGallianPBaizeSHorbyPWRaoulHMagassoubaNAntierensALomasCFayeOSallAAFransenKBuyzeJRavinettoRTiberghienPClaeysYDe CropMLynenLBahEISmithPGDelamouADe"/>
 <result pre="CropMLynenLBahEISmithPGDelamouADe WeggheleireAHabaNcollab: Ebola-Tx ConsortiumEvaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med2016374334226735992 15ChengYWongRSooYOWongWSLeeCKNgMHChanPWongKCLeungCBChengGUse of convalescent plasma"/>
 <result pre="Dis200524444615616839 16KoJHSeokHChoSYHaYEBaekJYKimSHKimYJParkJKChungCRKangESChoDMÃ¼llerMADrostenCKangCIChungDRSongJHPeckKRChallenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirus infection: a single centre experienceAntivir Ther20182361762229923831 17RajendranKKrishnasamyNRangarajanJRathinamJNatarajanMRamachandranAConvalescent plasma"/>
 <result pre="in Covid-19: Possible mechanisms of actionAutoimmun Rev20201910255432380316 19GarraudOHeshmatiFPozzettoBLefrereFGirotRSaillolALapercheSPlasma therapy against" exact="infectious" post="pathogens, as of yesterday, today and tomorrowTransfus Clin Biol201623394426775794"/>
 <result pre="22ZhangBLiuSTanTHuangWDongYChenLChenQZhangLZhongQZhangXZouYZhangSTreatment with convalescent plasma for critically ill patients with severe" exact="acute" post="respiratory syndrome coronavirus 2 infectionChest2020158e91332243945 23AhnJYSohnYLeeSHChoYHyunJHBaekYJJeongSJKimJHKuNSYeomJSRohJAhnMYChinBSKimYSLeeHYongDKimHOKimSChoiJYUse of convalescent plasma"/>
 <result pre="with convalescent plasma for critically ill patients with severe acute" exact="respiratory" post="syndrome coronavirus 2 infectionChest2020158e91332243945 23AhnJYSohnYLeeSHChoYHyunJHBaekYJJeongSJKimJHKuNSYeomJSRohJAhnMYChinBSKimYSLeeHYongDKimHOKimSChoiJYUse of convalescent plasma therapy"/>
 <result pre="convalescent plasma for critically ill patients with severe acute respiratory" exact="syndrome" post="coronavirus 2 infectionChest2020158e91332243945 23AhnJYSohnYLeeSHChoYHyunJHBaekYJJeongSJKimJHKuNSYeomJSRohJAhnMYChinBSKimYSLeeHYongDKimHOKimSChoiJYUse of convalescent plasma therapy in"/>
 <result pre="23AhnJYSohnYLeeSHChoYHyunJHBaekYJJeongSJKimJHKuNSYeomJSRohJAhnMYChinBSKimYSLeeHYongDKimHOKimSChoiJYUse of convalescent plasma therapy in two COVID-19 patients with" exact="acute" post="respiratory distress syndrome in KoreaJ Korean Med Sci202035e14932281317 24ZengQLYuZJGouJJLiGMMaSHZhangGFXuJHLinWBCuiGLZhangMMLiCWangZSZhangZHLiuZSEffect"/>
 <result pre="of convalescent plasma therapy in two COVID-19 patients with acute" exact="respiratory" post="distress syndrome in KoreaJ Korean Med Sci202035e14932281317 24ZengQLYuZJGouJJLiGMMaSHZhangGFXuJHLinWBCuiGLZhangMMLiCWangZSZhangZHLiuZSEffect of"/>
 <result pre="plasma therapy in two COVID-19 patients with acute respiratory distress" exact="syndrome" post="in KoreaJ Korean Med Sci202035e14932281317 24ZengQLYuZJGouJJLiGMMaSHZhangGFXuJHLinWBCuiGLZhangMMLiCWangZSZhangZHLiuZSEffect of convalescent plasma"/>
 <result pre="KoreaJ Korean Med Sci202035e14932281317 24ZengQLYuZJGouJJLiGMMaSHZhangGFXuJHLinWBCuiGLZhangMMLiCWangZSZhangZHLiuZSEffect of convalescent plasma therapy on" exact="viral" post="shedding and survival in patients with coronavirus disease 2019J"/>
 <result pre="therapy on viral shedding and survival in patients with coronavirus" exact="disease" post="2019J Infect Dis2020222384332348485 25SalazarEPerezKKAshrafMChenJCastilloBChristensenPAEubankTBernardDWEagarTNLongSWSubediSOlsenRJLevequeCSchwartzMRDeyMChavez-EastCRogersJShehabeldinAJosephDWilliamsGThomasKMasudFTalleyCDlouhyKGLopezBVHamptonCLavinderJGolliharJDMaranhaoACIppolitoGCSaavedraMOCantuCCYerramilliPPruittLMusserJMTreatment of coronavirus disease 2019 (COVID-19)"/>
 <result pre="patients with coronavirus disease 2019J Infect Dis2020222384332348485 25SalazarEPerezKKAshrafMChenJCastilloBChristensenPAEubankTBernardDWEagarTNLongSWSubediSOlsenRJLevequeCSchwartzMRDeyMChavez-EastCRogersJShehabeldinAJosephDWilliamsGThomasKMasudFTalleyCDlouhyKGLopezBVHamptonCLavinderJGolliharJDMaranhaoACIppolitoGCSaavedraMOCantuCCYerramilliPPruittLMusserJMTreatment of coronavirus" exact="disease" post="2019 (COVID-19) patients with convalescent plasmaAm J Pathol20201901680169032473109 26PerottiCBaldantiFBrunoRDel"/>
 <result pre="in 5,000 patientsJ Clin Invest20201304791479732525844 31SempleJWRebetzJKapurRTransfusion-associated circulatory overload and transfusion-related" exact="acute" post="lung injuryBlood20191331840185330808638 32SmattiMKAl ThaniAAYassineHMViral-induced enhanced disease illnessFront Microbiol20189299130568643 33WanYShangJSunSTaiWChenJGengQHeLChenYWuJShiZZhouYDuLLiFMolecular"/>
 <result pre="circulatory overload and transfusion-related acute lung injuryBlood20191331840185330808638 32SmattiMKAl ThaniAAYassineHMViral-induced enhanced" exact="disease" post="illnessFront Microbiol20189299130568643 33WanYShangJSunSTaiWChenJGengQHeLChenYWuJShiZZhouYDuLLiFMolecular mechanism for antibody-dependent enhancement of coronavirus"/>
 <result pre="epitopes in humans elicited both enhancing and neutralizing effects on" exact="infection" post="in non-human primatesACS Infect Dis2016236137627627203 35collab: Food and Drug"/>
 <result pre="plasmaAccessed 3 August 2020Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma 36collab: Korea Centers for" exact="Disease" post="Control and Prevention (KCDC)Guidelines for collecting convalescent plasma of"/>
 <result pre="to SARS-CoV-2 infectionClin Infect Dis2020[Epub ahead of print] 39HarvalaHMehewJRobbMLIjazSDicksSPatelMWatkinsNSimmondsPBrooksTJohnsonRGopalRRobertsDJZambonMcollab: NHS" exact="Blood" post="and Transplant Convalescent Plasma Testing GroupConvalescent plasma treatment for"/>
</results>
